Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145855 | 0.87 | ALDH1A1 (0.62) | ALDH1A1TSHRCYP3A4SMN1; SMN2ACHE | |
| SCHEMBL29587173 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP3A4SMN1; SMN2ACHE | |
| SCHEMBL5800828 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TSHRCYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL116606 | 0.84 | ALDH1A1 (0.69) | ALDH1A1CYP3A4SMN1; SMN2TDP1MAPK1 | |
| SCHEMBL7188789 | 0.82 | ALDH1A1 (0.67) | ALDH1A1TSHRCYP3A4SMN1; SMN2ACHE | |
| SCHEMBL21611343 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4SMN1; SMN2TDP1MAPK1 | |
| SCHEMBL30365875 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4SMN1; SMN2TDP1MAPK1 | |
| Ammonia Solution, Strong SCHEMBL10988442 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4SMN1; SMN2TDP1MAPK1 | |
| Hydrochloric Acid SCHEMBL3275940 | 0.81 | ALDH1A1 (0.65) | ALDH1A1CYP3A4SMN1; SMN2TDP1MAPK1 | |
| SCHEMBL12501 | 0.81 | ALDH1A1 (0.73) | ALDH1A1TSHRCYP3A4ACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112563571-A | Additive for battery, secondary battery, battery module, battery pack and device | 宁德时代新能源科技股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| CN-111909113-A | Synthesis method of 2-substituted benzothiazole compound under catalyst-free and additive-free conditions | 衡阳师范学院 | 2020-11-10 | — | — | CN | claimed |
| CN-111704590-A | Synthesis method of iron-catalyzed 2-arylbenzothiazole compound | 衡阳师范学院 | 2020-09-25 | — | — | CN | claimed |
| US-9249091-B2 | Post-treated sulfurized salt of an alkyl-substituted hydroxyaromatic composition | CHEVRON ORONITE COMPANY LLC (US) | 2016-02-02 | — | — | US | claimed |
| US-20130165359-A1 | POST-TREATED SULFURIZED SALT OF AN ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | CHEVRON ORONITE COMPANY LLC (US) | 2013-06-27 | — | — | US | claimed |
| US-7056986-B2 | ethylene monomer can be a vinyl ketone, ether, ester, halide, nitrile, aromatic, or an allyl ether; acrylic monomer can be a mono- or diacid or monoester of a diacid; a monoamine, a guanidine compound, and an aromatic diamine; improved vulcanizability, balance between processability and compression set | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-06-06 | — | — | US | claimed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| WO-2024182747-A2 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4289830-A1 | NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE | Ajou University Industry-Academic Cooperation Foundation (KR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | NOVOGEN RESEARCH PTY LIMITED (AU) | 2008-11-20 | — | — | US | disclosed |
| US-7419998-B2 | Therapeutic methods and compositions involving isoflavones | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-02 | — | — | US | disclosed |
| US-7056986-B2 | ethylene monomer can be a vinyl ketone, ether, ester, halide, nitrile, aromatic, or an allyl ether; acrylic monomer can be a mono- or diacid or monoester of a diacid; a monoamine, a guanidine compound, and an aromatic diamine; improved vulcanizability, balance between processability and compression set | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-06-06 | — | — | US | disclosed |
| US-20040266922-A1 | Ethylene-acrylic copolymer rubber composition | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-1449881-A1 | ACRYLIC RUBBER COMPOSITION | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-4560746-A | MONOAZO DYES, 2-(2-QUINOLYL)-1,3-INDANEDIONESULFONIC ACID | THE HILTON-DAVIS CHEMICAL CO. (US) | 1985-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885TSHR 3668/4885CYP3A4 3136/4885 |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | ALDH1A1 685/4885TSHR 2676/4885CYP3A4 402/4885 |
| US-20130165359-A1 | POST-TREATED SULFURIZED SALT OF AN ALKYL-SUBSTITUTED HYDROXYAROMATIC COMPOSITION | TST, PAH, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ALDH1A1 814/4885TSHR 4066/4885CYP3A4 2118/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885TSHR 3668/4885CYP3A4 3136/4885 |
| US-20080287528-A1 | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES | C1R, ESRRA, ESRRB | ALDH1A1 1726/4885TSHR 1121/4885CYP3A4 1461/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | ALDH1A1 980/4885TSHR 3668/4885CYP3A4 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.